HiloProbe is a biotechnology company founded 2016. The founders consist of a group of scientists, who have collaborated for more than 15 years in an academic setting, and produced high quality original research focusing on the development of clinically useful biomarkers for colorectal cancer. The disturbing fact that only half of all colorectal cancer patients are cured – even after successful surgery – has been an incentive to develop the academic results into a clinically available product.
The research has been focused on analysis of the regional lymph nodes in the abdomen surrounding the primary tumor in the colon. The reason is that the lymph node is the first site where metastasizing cancer cells will occur. We have now discovered a limited number of biomarkers that, when analyzed together, identify cancer cells in the lymph node and grade cancer cell aggressiveness i.e. their propensity to metastasize to distant sites. A product (ColoNode®) based on biomarker mRNA analysis is under development. The aim is to bring ColoNode® to the market to save people´s lives and aid in the development of more efficient treatment of colorectal cancer.
Fast and detailed lymph node examination following colorectal cancer surgery, enabling accurate selection of patients in need of postoperative treatment.
BOARD OF DIRECTORS
Chairman of the Board
Former co-founder and CEO of Boule Diagnostics AB (listed on Nasdaq 2011) 1996 – 2017. Experienced Chief Executive Officer with a demonstrated track record of growing a global business in the medical device industry. Strong business development and professional skills in Sales and Marketing as well as Research and Development within Medical Devices and Life Sciences. Chairman of Scandinavian Realheart, Devyser and Capitainer AB, Sweden, Board Member of Cavidi and Astrego Diagnostics AB, Sweden.
Sten Hammarström – born 1940, Chairman since 2016 – is a Swedish Ph. D. in Immunology at Stockholm University and Professor emeritus of Immunology at Umeå University, Umeå, Sweden. Active in research on colorectal cancer, inflammatory bowel disease and celiac disease with focus on biomarkers and gene expression analysis for more than 40 years. Abbott award 1998.
Gudrun Lindmark – born 1953. Board member since 2016 – is a Swedish M.D., Ph. D. in Surgery at Uppsala University. Active in clinical treatment and research in colorectal cancer. Involved in development of guidelines for treatment of colorectal cancer. Currently private practice in Malmö, recently adjungated Professor of Surgery, Lund University, Sweden.
Born 1962. Board member since autumn 2018. Master in Biology GU and SU and an MBA at IHM business school. Has been working in the life Science industry in more than 30 years in various positions. As laboratory Engineer AZ Safety Assessment, in Sales, Product management and leading positions in distribution and direct sales companies.
Site Manager at Life Technologies Sweden 1994 -1999. CEO and part owner of Nordic Biolabs AB 2000 – present. Is also COB in red hot diagnostics AB since 2015, a company that facilitates the commercialization’s of scientist’s innovation in diagnostics and brings them to market.
Lina Olsson – born 1981. CEO since 2016 – is a Swedish graduate Master of Science in Engineering Biology and has a Ph. D. in Immunology from Umeå University, Sweden (2011). More than 8 years of experience in biomarker research and 4 years of product development and business development.